TICKERNERD
Menu
HAEHAEHealthcare · Medical Devices

HAE Stock Forecast: Haemonetics Corp. Price Predictions for 2026-2027

Last close, 18 Sept 2026
$108
+0.74% on the day

The 11 Wall Street analysts covering Haemonetics Corp. hold a median 12-month price target of $113 — +3.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 99 of 100 as at 19 Sept 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$4.9B
Ticker Nerd rank
99 / 100
Median analyst target
$113
Analysts covering
11
Revenue$339.4M+5.6% y/y
Operating income$57.5M
Net income$33.0M
Free cash flow$44.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+5.6%
1M
+3.6%
YTD
+35.2%
1Y
+111.9%
From 52W high
−0.4%
From 52W low
+127.4%
$48
$109
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

HAE stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Haemonetics Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026
99 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Issuance
97
Momentum
93
Accruals
92
Volatility
91
Revisions
86
Quality
85
Value
83
Growth
46
Size
23

Issuance (97): The share count has been shrinking and the company is not leaning on new borrowing.

Growth (46): Sales and profits are flat, shrinking, or growing more slowly than they were.

Size (23): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

HAE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on HAE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$40$60$80$100$120Oct 25Jan 26Apr 26Jul 26HAEHigh $125Median $113Low $86

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says11 analysts
8 Buy3 Hold0 Sell
Low $86Median $113High $125

The green dot is the last close — the median target sits +3.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 9 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
17 Sept 2026CitigroupUpgradeBuy$92 → $123
3 Sept 2026Raymond JamesMaintainsOutperform$105 → $125
21 Aug 2026BairdMaintainsOutperform$96 → $119
21 Aug 2026BairdMaintainsOutperform—
19 Aug 2026Barrington ResearchMaintainsOutperform$95 → $118
19 Aug 2026Barrington ResearchMaintainsOutperform—
18 Aug 2026BTIGMaintainsBuy$96 → $110
18 Aug 2026BTIGMaintainsBuy—
7 Aug 2026CitigroupMaintainsNeutral—
7 Aug 2026CitigroupMaintainsNeutral$79 → $92
7 Aug 2026JP MorganMaintainsNeutral$62 → $86
7 Aug 2026JP MorganMaintainsNeutral—
6 Aug 2026BTIGMaintainsBuy$84 → $96
6 Aug 2026BTIGMaintainsBuy—
15 July 2026MizuhoMaintainsOutperform—
15 July 2026MizuhoMaintainsOutperform$85 → $90
26 June 2026BTIGReiteratesBuy$84
26 June 2026BTIGReiteratesBuy—
17 June 2026BTIGReiteratesBuy—
15 June 2026MizuhoMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. HAE appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

HAE vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Sept 2026, Haemonetics Corp. returned +111.9% against +16.3% for the S&P 500, dividends included.

HAE vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180200220Oct 25Jan 26Apr 26Jul 26HAES&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

HAE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+1.5%
Analysts raising
11
Analysts cutting
0
Fundamentals

Haemonetics Corp. (HAE) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
52.1×

Cheaper than 14% of US stocks

Price / sales
3.6×

Cheaper than 34% of US stocks

Price / book
5.9×

Cheaper than 17% of US stocks

EV / EBITDA
16.4×

Cheaper than 20% of US stocks

Growth & margins
Revenue growth (YoY)
5.6%

Higher than 40% of US stocks

Earnings growth (YoY)
−3.0%

Higher than 33% of US stocks

Gross margin
59.8%

Higher than 73% of US stocks

Operating margin
17.9%

Higher than 76% of US stocks

Net margin
7.1%

Higher than 64% of US stocks

Returns & dividend
Return on equity
11.2%

Higher than 66% of US stocks

Return on assets
6.6%

Higher than 83% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Haemonetics Corp. (HAE) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Haemonetics Corp. has a market value of $4.9B and an enterprise value of $5.9B.

  • Revenue in the twelve months to 30 June 2026: $1.4B. The latest quarter grew 5.6% year on year.

  • Net income over the same four quarters: $96.3M, a 7.1% net margin.

  • Diluted earnings per share, trailing twelve months: $2.04.

  • Free cash flow in the twelve months to 30 June 2026: $291.2M, after $36.9M of capital spending.

  • Shares outstanding: 45.5M.

  • Trailing P/E: 52.1×; forward P/E: 18.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Haemonetics Corp. employs 3,009 people — $449K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 19 Sept 2026

Data provided by Twelve Data

Peers

HAE vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
HAEHaemonetics Corp.$4.9B
99
ITGRInteger Holdings Corp.$4.4B
74
LIVNLivaNova PLC$4.3B
97
IRTCiRhythm Holdings, Inc.$3.6B
74
TMDXTransMedics Group, Inc.$3.0B
29
NEOGNeogen Corp.$2.8B
97
BRKRBruker Corp.$9.3B
87

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Haemonetics Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest HAE news & analysis

PAHC vs. HAE: Which Stock Should Value Investors Buy Now?

Zacks Investment Research · 18 Sept 2026neutral

Zacks Investment Research compares Phibro Animal Health (PAHC) and Haemonetics (HAE), both in the Medical - Products sector, considering which stock offers the better value opportunity for investors. The piece poses this comparison without yet resolving which company holds the advantage.

Why it matters — The piece highlights Haemonetics' positioning within the medical products sector and how value investors may evaluate it against a peer.

Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics

GlobeNewsWire · 15 Sept 2026positive

Orchestra BioMed received a $6.1 million milestone payment on September 14, 2026, in connection with Haemonetics' acquisition of Vivasure. This follows approximately $5 million received in January 2026, bringing total cash proceeds to about $11 million, with eligibility for up to roughly $10 million more through future revenue earnouts.

Why it matters — HAE watchers would care because this progress payment signals the completion of a key integration milestone tied to the Vivasure acquisition and the potential for continued earnout-related cash flows related to the deal.

GEHC vs. HAE: Which Stock Is the Better Value Option?

Zacks Investment Research · 31 Aug 2026neutral

Zacks Investment Research published a comparison of GE HealthCare Technologies (GEHC) and Haemonetics (HAE) as potential value investments in the Medical - Products sector. The article poses the question of which of the two stocks is the more attractive option for value investors.

Why it matters — The piece places Haemonetics in a direct value-investing comparison with a major industry peer, which may inform how investors evaluate HAE's relative valuation.

4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gains

Zacks Investment Research · 24 Aug 2026neutral

Zacks Research highlights four gene-editing biotech stocks — CRSP, NTLA, BEAM and EDIT — as offering distinct long-term opportunities spanning commercial validation, late-stage catalysts and early-stage programs.

Why it matters — This item focuses on unrelated gene-editing biotechs and contains no information about Haemonetics, so it does not affect the outlook for HAE.

Haemonetics: Worth Speculating On This Recurring Medtech Plasma Model

Seeking Alpha · 21 Aug 2026positive

The article describes Haemonetics as a medtech company increasingly generating recurring revenues from plasma consumables, supported by its higher-margin MedSurg segment, which together provide a durable growth profile. It notes that a recent agreement with CSL could expand this potential.

Why it matters — HAE watchers would care because the piece highlights the company's shift toward recurring plasma revenue and a new CSL agreement that could broaden its growth prospects.

FAQ

Frequently asked questions about HAE stock

What is the HAE stock price forecast for 2026-2027?

The 11 Wall Street analysts covering Haemonetics Corp. have a median 12-month price target of $113, with estimates ranging from $86 to $125. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is HAE stock a buy right now?

Of the 11 analysts covering Haemonetics Corp., 8 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Haemonetics Corp. 99 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank HAE?

As at 19 Sept 2026, Haemonetics Corp. ranks 99 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (97 of 100).

Will HAE stock go up?

No one can know that. What the data says: the median 12-month target from 11 analysts implies +3.8% from the last close, and Ticker Nerd's factor model ranks Haemonetics Corp. 99 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the HAE stock forecast for 2030?

No analyst covering Haemonetics Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HAE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $86 to $125 over the next 12 months.

How has HAE stock performed over the past year?

Haemonetics Corp. returned +111.9% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Haemonetics Corp. do?

Haemonetics Corporation is a medical technology company that develops products and services for blood and plasma collection, hospital transfusion management, and selected interventional procedures. Its Plasma segment provides automated collection systems, donor management software, and related disposables that support plasma centers and improve operational efficiency.

What is the latest news on HAE?

The most recent item we track (Zacks Investment Research, 18 Sept 2026): "PAHC vs. HAE: Which Stock Should Value Investors Buy Now?". Zacks Investment Research compares Phibro Animal Health (PAHC) and Haemonetics (HAE), both in the Medical - Products sector, considering which stock offers the better value opportunity for investors. The piece poses this comparison without yet resolving which company holds the advantage.

Company

About Haemonetics Corp.

Haemonetics Corporation is a medical technology company that develops products and services for blood and plasma collection, hospital transfusion management, and selected interventional procedures. Its Plasma segment provides automated collection systems, donor management software, and related disposables that support plasma centers and improve operational efficiency. The Blood Center segment offers apheresis and whole blood collection solutions used to collect and process blood components for transfusion. The Hospital segment includes blood management technologies, hemostasis management systems, surgical blood salvage products, vascular closure devices, and sensor-guided tools designed to support clinical decision-making and procedural performance. Headquartered in Boston, Massachusetts, Haemonetics serves healthcare providers and collection centers across global markets.

CEO Mr. Christopher A. Simon · 3,009 employees · United States · https://www.haemonetics.com